Acerus Pharmaceuticals Corporation
ASP.TO
Toronto Stock Exchange0.36
CAD
- -
- -
Acerus Pharmaceuticals Corporation
ASP.TO
(Toronto Stock Exchange)
Recent
price
0.36
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Acerus Pharmaceuticals Corporation historically operated as a specialty pharmaceutical entity, dedicated to the advancement, production, commercialization, and distribution of medical treatments for both men's and women's health. The company's prior offerings included Natesto, a unique nasal gel prescribed for testosterone replacement therapy in adult males suffering from hypogonadism, and Noctiva, a vasopressin analogue used to manage nocturia linked to nocturnal polyuria in adults. Its development portfolio encompassed Lidbree, a rapid-acting lidocaine formulation designed for vaginal mucosal tissue delivery via a proprietary device; Stendra, a PDE5 inhibitor for addressing erectile dysfunction; Tefina, a product in clinical stages targeting female sexual dysfunction; and various Noctiva combination products undergoing preclinical development for conditions such as benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. Acerus also leveraged its proprietary TriVair technology platform for pulmonary and nasal drug delivery. Originating in 2008 and previously known as Trimel Pharmaceuticals Corporation before its renaming in September 2015, the company maintained its headquarters in Mississauga, Canada. In early 2023, Acerus faced substantial financial challenges, leading it to seek creditor protection under Canada's Companies' Creditors Arrangement Act and Chapter 15 bankruptcy in the United States. Consequently, its common shares were delisted from the Toronto Stock Exchange in March 2023. By July 2023, following a court-approved transaction, Acerus Pharmaceuticals Corporation ceased to be a publicly traded entity, with all previously issued common shares cancelled without consideration as it became a fully owned subsidiary of First Generation Capital Inc.